探讨桃红饮体外通过VEGFC通路对巨噬细胞介导的淋巴管生成的抑制作用

李斯锦; 冯骁腾; 王怡茹; 刘萍

doi:10.3969/j.issn.1006-2157.2023.12.008

您当前的位置：

首页 >

文章列表页 >

探讨桃红饮体外通过VEGFC通路对巨噬细胞介导的淋巴管生成的抑制作用

实验研究 | 更新时间：2024-01-03

- 探讨桃红饮体外通过VEGFC通路对巨噬细胞介导的淋巴管生成的抑制作用
- Taohongyin inhibits the VEGFC pathway in vitro and reduces macrophage-mediated lymphangiogenesis
- 北京中医药大学学报 2023年46卷第12期页码：1670-1683
- 作者机构：
  
  上海中医药大学附属龙华医院　上海　200032
- 作者简介：
  
  李斯锦，女，在读博士生
  #刘萍，女，教授，主任医师，博士生导师，主要研究方向：中西医结合防治动脉粥样硬化相关心脑血管疾病，E-mail：liuping5156@sina.com
- 基金信息：
  
  国家自然科学基金面上项目(82074200;81873117);国家自然科学基金青年项目(82204849)
- DOI：10.3969/j.issn.1006-2157.2023.12.008
  中图分类号： R285.5
- 纸质出版日期：2023-12-30，
  
  网络出版日期：2023-12-06，
  
  收稿日期：2023-07-08，
- 稿件说明：
移动端阅览
李斯锦, 冯骁腾, 王怡茹, 等. 探讨桃红饮体外通过VEGFC通路对巨噬细胞介导的淋巴管生成的抑制作用[J]. 北京中医药大学学报, 2023,46(12):1670-1683.

LI Sijin, FENG Xiaoteng, WANG Yiru, et al. Taohongyin inhibits the VEGFC pathway in vitro and reduces macrophage-mediated lymphangiogenesis[J]. Journal of Beijing University of Traditional Chinese Medicine, 2023,46(12):1670-1683.
李斯锦, 冯骁腾, 王怡茹, 等. 探讨桃红饮体外通过VEGFC通路对巨噬细胞介导的淋巴管生成的抑制作用[J]. 北京中医药大学学报, 2023,46(12):1670-1683. DOI： 10.3969/j.issn.1006-2157.2023.12.008.

LI Sijin, FENG Xiaoteng, WANG Yiru, et al. Taohongyin inhibits the VEGFC pathway in vitro and reduces macrophage-mediated lymphangiogenesis[J]. Journal of Beijing University of Traditional Chinese Medicine, 2023,46(12):1670-1683. DOI： 10.3969/j.issn.1006-2157.2023.12.008.

摘要

目的

探讨桃红饮(桃仁、红花、川芎、当归尾、威灵仙)治疗动脉粥样硬化，调控巨噬细胞介导的淋巴管生成的分子机制。

方法

采用超高效液相色谱质谱法鉴定桃红饮有效成分。以慢病毒转染方法，构建血管内皮生长因子C(VEGFC)基因过表达的RAW264.7巨噬细胞(OE-VEGFC)与空载体对照RAW264.7巨噬细胞(OE-VEHICLE)。用人氧化低密度脂蛋白(20 mg/L)与脂多糖(100 μg/L)干预RAW264.7巨噬细胞或OE-VEGFC构建动脉粥样硬化细胞模型(造模

RAW264.7

及造模

OE-VEGFC

)。CCK-8法测定桃红饮的最佳给药质量浓度。构建RAW264.7巨噬细胞与小鼠淋巴管内皮细胞(MLECs)Transwell共培养模型。划痕实验检测细胞损伤修复情况；结晶紫染色检测细胞的迁移情况；管形成实验测定细胞的管腔形成能力；酶联免疫吸附剂测定法检测细胞上清液中VEGFC、白细胞介素6(IL-6)、诱导型一氧化氮合酶(iNOS)的含量；免疫荧光标记法检测细胞VEGFC含量；实时荧光定量PCR检测VEGFC、淋巴管内皮细胞表面受体(FLT4)、平足蛋白(PDPN)、IL-6、iNOS的mRNA表达；蛋白质印迹法检测VEGFC、FLT4、HIF-1α、淋巴管内皮透明质酸受体-1(LYVE-1)、同源异型盒基因转录因子-1(Prox-1)、IL-6、iNOS的蛋白表达。

结果

桃红饮中含有22种主要有效成分，其中，羟基红花黄色素A(23.3%)及D-苦杏仁苷(23.8%)含量较高。选择20 mg/L作为桃红饮的给药最佳质量浓度。OE-VEGFC及OE-VEHICLE转染效率为80%以上，OE-VEGFC巨噬细胞构建成功。与正常对照组相比，造模RAW264.7组MLECs向划痕区域愈合的速度增快、细胞迁移数增多、管腔生成数增加(均

0.05)，VEGFC荧光表达量增加，细胞上清中VEGFC、IL-6、iNOS含量增加(均

0.05)，VEGFC、FLT4、PDPN、IL-6、iNOS的mRNA表达增加(均

0.05)，VEGFC、FLT4、HIF-1α、LYVE-1、Prox-1、IL-6、iNOS的蛋白表达增加(均

0.05)；桃红饮可逆转上述指标(均

0.05)。造模

OE-VEGFC

组与造模

RAW264.7

组相比，上述指标增加(均

0.05)；与桃红饮＋造模

RAW264.7

组相比，桃红饮＋造模

OE-VEGFC

组上述指标增加(均

0.05)；与造模

OE-VEGFC

组比较，桃红饮＋造模

OE-VEGFC

组上述指标减少(均

0.05)。

结论

桃红饮可能通过抑制VEGFC通路减少巨噬细胞介导的淋巴管形成。

Abstract

Objective

We aimed to explore whether

Taohongyin

(peach seed

safflower

Sichuan lovage rhizome

Chinese angelica root-tip

and Chinese clematis root) treats atherosclerosis by regulating macrophage-mediated lymphangiogenesis.

Methods

The effective components of

Taohongyin

were identified by UPLC-Q-TOF-MS. RAW264.7 macrophages were transfected with a lentiviral vascular endothelial growth factor C (VEGFC) overexpression construct

a VEGFC knockdown construct (OE-VEGFC)

and empty vector (OE-VEHICLE). The atherosclerotic cell model was constructed on RAW264.7 macrophages ( Model

RAW264.7

)or on OE-VEGFC (Model

OE-VEGFC

) by intervention with human oxidized low density lipoprotein (20 mg/L) and lipopolysaccharide (100 μg/L). The optimal concentration of

Taohongyin

was determined by the CCK-8 method. A Transwell co-culture model of RAW264.7 macrophages and mouse lymphatic endothelial cells (MLECs) was constructed. Wound healing was assessed by the scratch test. Migration of cells was analyzed by a Transwell assay followed by crystal violet staining. Tube formation was analyzed by the tube formation assay. The contents of VEGFC

interleukin-6 (IL-6)

and inducible nitric oxide synthase (iNOS) in the supernatant were determined by ELISA. The VEGFC content was determined by immunofluorescence labeling. The mRNA levels of VEGFC

lymphatic endothelial cell surface receptor (FLT4)

podoplanin (PDPN)

IL-6

and iNOS were determined by real-time fluorescence quantitative PCR. The protein expression levels of VEGFC

FLT4

HIF-1α

lymphatic vessel endothelial hyaluronic receptor 1 (LYVE-1)

homeobox gene transcription factor 1 (Prox-1)

IL-6

and iNOS were determined by Western blotting.

Results

UPLC-Q-TOF-MS identified 22 main active components in

Taohongyin

in which hydroxysafflor yellow A (23.3%) and D-amygdalin (23.8%) were at the highest levels. A

Taohongyin

concentration of 20 mg/L was selected as the optimal concentration. The transfection efficiency of OE-VEGFC and OE-VEHICLE was more than 80%

indicating that the RAW264.7 macrophage VEGFC overexpression model was successfully constructed. Compared with the normal control group

the wound healing capacity of MLECs was significantly increased

cell migration and tube formation were enhanced (all

0.05)

VEGFC fluorescence was increased (all

0.05)

the contents of VEGFC

IL-6

and iNOS in the supernatant were increased (all

0.05)

the mRNA expressions of VEGFC

FLT4

PDPN

IL-6

and iNOS were increased (all

0.05)

and the protein expressions of VEGFC

FLT4

HIF-1α

LYVE-1

Prox-1

IL-6

and iNOS were increased ( all

0.05) in the Model

RAW264.7

group. After intervention with

Taohongyin

of 20 mg/L

all the indicators were decreased (all

0.05).Compared with the Model

RAW264.7

group

all the indicators in the Model

OE-VEGFC

group were increased(all

0.05). Compared with the

Taohongyin

+ Model

RAW264.7

group

all the indicators in the

Taohongyin

+ Model

OE-VEGFC

group were increased(all

0.05). Compared with the Model

OE-VEGFC

group

all the indicators in the

Taohongyin

+ Model

OE-VEGFC

group were decreased(all

0.05).

Conclusion

Taohongyin

may reduce macrophage-mediated lymphangiogenesis by inhibiting the VEGFC pathway.

关键词

桃红饮动脉粥样硬化RAW264.7巨噬细胞小鼠淋巴管内皮细胞淋巴管羟基红花黄色素A

Keywords

TaohongyinatherosclerosisRAW264.7 macrophage cellmouse lymphatic endothelial cellslymphatic vesselshydroxysafflower yellow A

references

GUSEV E, SARAPULTSEV A. Atherosclerosis and inflammation: Insights from the theory of general pathological processes[J/OL]. Int J Mol Sci, 2023, 24(9)：7910[2023－05－07].https://www.mdpi.com/1422-0067/24/9/7910https://www.mdpi.com/1422-0067/24/9/7910.

WU JY, HE SP, SONG ZK, et al. Macrophage polarization states in atherosclerosis[J/OL]. Front Immunol, 2023, 3(14)：1185587[2023－05－17].https://www.frontiersin.org/articles/10.3389/fimmu.2023.1185587/fullhttps://www.frontiersin.org/articles/10.3389/fimmu.2023.1185587/full.

KUTKUT I, MEENS MJ, MCKEE TA, et al. Lymphatic vessels: an emerging actor in atherosclerotic plaque development[J]. Eur J Clin Invest, 2015, 45(1): 100－108.

MIYAZAKI A. Hypercholesterolemia and lymphatic defects: The chicken or the egg[J]. Front Cardiovasc Med, 2021，23(8): 21－29.

PETKOVA M, KRAFT M, STRITT S, et al. Immune-interacting lymphatic endothelial subtype at capillary terminals drives lymphatic malformation[J/OL]. J Exp Med, 2023, 220(4)：e20220741[2023－05－07].https://rupress.org/jem/article/220/4/e20220741/213817/Immuneinteracting-lymphatic-endothelial-subtypehttps://rupress.org/jem/article/220/4/e20220741/213817/Immuneinteracting-lymphatic-endothelial-subtype.

FLISTER MJ, WILBER A, HALL KL, et al. Inflammation induces lymphangiogenesis through up-regulation of VEGFR－3 mediated by NF-kappaB and Prox1[J]. Blood, 2010, 115(2): 418－429.

LI QY, ZHOU CX, ZHAO K, et al. Lymphatic endothelial sphingosine 1－phosphate receptor 1 enhances macrophage clearance via lymphatic system following myocardial infarction[J/OL]. Front Cardiovasc Med, 2022，8(9)：872102[2022－05－17].https://www.frontiersin.org/articles/10.3389/fcvm.2022.872102/fullhttps://www.frontiersin.org/articles/10.3389/fcvm.2022.872102/full.

FENG XT, DU M, LI SJ, et al. Hydroxysafflor yellow A regulates lymphangiogenesis and inflammation via the inhibition of PI3K on regulating AKT/mTOR and NF－κB pathway in macrophages to reduce atherosclerosis in ApoE－/－ mice[J/OL]. Phytomedicine, 2023, 112：154684[2023－05－17].https://linkinghub.elsevier.com/retrieve/pii/S0944711323000442https://linkinghub.elsevier.com/retrieve/pii/S0944711323000442.

LI SJ, LIU P, FENG XT, et al. Mechanism of Tao Hong Decoction in the treatment of atherosclerosis based on network pharmacology and experimental validation[J/OL]. Front Cardiovasc Med, 2023, 10：1111475[2023－05－27].https://www.frontiersin.org/articles/10.3389/fcvm.2023.1111475/fullhttps://www.frontiersin.org/articles/10.3389/fcvm.2023.1111475/full.

冯骁腾，杜敏，张一凡，等．桃红饮减轻ApoE－/－小鼠动脉粥样硬化并发非酒精性脂肪肝氧化应激损伤和纤维化的作用研究[J].时珍国医国药，2023，34(1)：1－5.

SIRONI M, CONTI A, BERNASCONI S, et al. Generation and characterization of a mouse lymphatic endothelial cell line[J]. Cell Tissue Res, 2006, 325(1)：91－100.

LIANG QQ, JU YW, CHEN Y, et al. Lymphatic endothelial cells efferent to inflamed joints produce iNOS and inhibit lymphatic vessel contraction and drainage in TNF-induced arthritis in mice[J/OL]. Arthritis Res Ther, 2016, 18：62[2023－05－27]. https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-016-0963-8https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-016-0963-8.

LIANG QQ, ZHANG L, XU H, et al. Lymphatic muscle cells contribute to dysfunction of the synovial lymphatic system in inflammatory arthritis in mice[J/OL]. Arthritis Res Ther, 2021, 23(1)：58[2023－05－27].https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-021-02438-6https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-021-02438-6.

RAN S, MONTGOMERY KE. Macrophage-mediated lymphangiogenesis: the emerging role of macrophages as lymphatic endothelial progenitors[J]. Cancers (Basel), 2012, 4(3)：618－657.

HALL KL, VOLK-DRAPER LD, FLISTER MJ, et al. New model of macrophage acquisition of the lymphatic endothelial phenotype[J/OL]. PLoS One, 2012, 7(3)：e31794[2022－10－07].https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0031794https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0031794.

TABRIZI ZB, AHMED NS, HORDER JL, et al. Transcription factor control of lymphatic quiescence and maturation of lymphatic neovessels in development and physiology[J/OL]. Front Physiol, 2021，12, 672987[2023－05－17].https://www.frontiersin.org/articles/10.3389/fphys.2021.672987/fullhttps://www.frontiersin.org/articles/10.3389/fphys.2021.672987/full.

CHEN SM, ZHAO CK, YAO LC, et al. Aiphanol, a multi-targeting stilbenolignan, potently suppresses mouse lymphangiogenesis and lymphatic metastasis[J]. Acta Pharmacol Sin, 2023, 44(1)：189－200.

GORDON EJ, RAO S, POLLARD JW, et al. Macrophages define dermal lymphatic vessel calibre during development by regulating lymphatic endothelial cell proliferations[J]. Development, 2010, 137(22)：3899－3910.

CAHILL TJ, SUN X, RAVAUD C, et al. Tissue－resident macrophages regulate lymphatic vessel growth and patterning in the developing heart[J/OL]. Development, 2021, 148(3)：dev194563[2023－05－07].https://journals.biologists.com/dev/article/148/3/dev194563/223255/Tissue-resident-macrophages-regulate-lymphatichttps://journals.biologists.com/dev/article/148/3/dev194563/223255/Tissue-resident-macrophages-regulate-lymphatic.

SINGLA B, AITHBATHULA RV, PERVAIZ N, et al. CD47 activation by thrombospondin－1 in lymphatic endothelial cells suppresses lymphangiogenesis and promotes Atherosclerosis[J]. Arterioscler Thromb Vasc Biol, 2023, 43(7)：1234－1250.

PETROVA TV, KOH GY. Biological functions of lymphatic vessels[J/OL]. Science, 2020，369(6500)：eaax4063[2022－10－07].https://www.science.org/doi/10.1126/science.aax4063https://www.science.org/doi/10.1126/science.aax4063.

KAIPAINEN A, KORHONEN J, MUSTONEN T, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development[J]. Proc Natl Acad Sci USA, 1995, 92(8)：3566－3570.

LAWRANCE W, BANERJI S, DAY AJ, et al. Binding of hyaluronan to the native lymphatic vessel endothelial receptor LYVE－1 is critically dependent on receptor clustering and hyaluronan organization[J]. J Biol Chem, 2016, 291(15)：8014－8030.

MARUYAMA Y, MARUYAMA K, KATO Y, et al. The effect of podoplanin inhibition on lymphangiogenesis under pathological conditions[J]. Invest Ophthalmol Vis Sci, 2014, 55(8)：4813－4822.

KAZENWADEL J, VENUGOPAL P, OSZMIANA A, et al. A Prox1 enhancer represses haematopoiesis in the lymphatic vasculature[J]. Nature, 2023, 614(7947)：343－348.

WIGLE JT, OLIVER G. Prox1 function is required for the development of the murine lymphatic system[J]. Cell, 1999, 98(6)：769－778.

JOHNSON NC, DILLARD ME, BALUK P, et al. Lymphatic endothelial cell identity is reversible and its maintenance requires Prox1 activity[J]. Genes Dev, 2008, 22(23)：3282－3291.

LIAN G, LI XP, ZHANG LQ, et al. Macrophage metabolic reprogramming aggravates aortic dissection through the HIF1α－ADAM17 pathway[J]. Ebio Medicine，2019, 49：291－304.

TARBELL J, MAHMOUD M, CORTI A, et al. The role of oxygen transport in atherosclerosis and vascular disease[J/OL]. J R Soc Interface, 2020, 17：20190732[2023－05－17].https://royalsocietypublishing.org/doi/10.1098/rsif.2019.0732https://royalsocietypublishing.org/doi/10.1098/rsif.2019.0732.

JIA XM, BUCKLEY L, SUN C, et al. Association of interleukin－6 and interleukin－18 with cardiovascular disease in older adults: Atherosclerosis risk in communities study[J/OL]. Eur J Prev Cardiol, 2023, 12：zwad197[2023－06－15].https://academic.oup.com/eurjpc/advance-article-abstract/doi/10.1093/eurjpc/zwad197/7194126?redirectedFrom=fulltext&login=falsehttps://academic.oup.com/eurjpc/advance-article-abstract/doi/10.1093/eurjpc/zwad197/7194126?redirectedFrom=fulltext&login=false.

WILMES V, KUR IM, WEIGERT A, et al. iNOS expressing macrophages co-localize with nitrotyrosine staining after myocardial infarction in humans[J/OL]. Front Cardiovasc Med, 2023, 10：1104019[2023－06－15].https://pubmed.ncbi.nlm.nih.gov/37063955/https://pubmed.ncbi.nlm.nih.gov/37063955/.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

电针对动脉粥样硬化家兔腹腔巨噬细胞胆固醇逆转运受体表达的影响

血管软化丸调控Nrf2/xCT/GPX4通路抑制血管内皮细胞铁死亡改善动脉粥样硬化的作用机制

基于“寒中于暮”探析动脉粥样硬化的病因病机

从阴火病络视角探讨泛血管疾病的发病机制

基于“肝心同病”探析代谢相关脂肪性肝病合并动脉粥样硬化的病机与治疗思路